Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.

Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 2006 Sep 01; 108(5):1478-84.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Agents
Benzamides
Bone Marrow Transplantation
Clinical Trials, Phase III as Topic
Cytarabine
Disease Progression
Female
Humans
Imatinib Mesylate
Interferon-alpha
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Male
Middle Aged
Piperazines
Pyrimidines
Retrospective Studies
Splenomegaly
Survival Analysis
Treatment Failure
Treatment Outcome

authors with profiles

Richard A. Larson